Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What CAGR Is Anticipated for the Gene Therapy On Neurological Diseases Market Through 2029?#_x000D_
The market for gene therapy in neurological conditions has witnessed significant expansion recently, and is projected to increase from $3.13 billion in 2024 to $3.55 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 13.2%. This development in the historical period is due to rising instances of neurological issues, a surge in interest for individualized medicinal treatments, escalated investment in biotechnological research and development, amplified clinical trial operations, and an increased number of authorizations for gene treatments._x000D_
_x000D_
The neurologic disease gene therapy market is anticipated to experience swift growth in the forthcoming years, swelling to a size of $5.76 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 12.9%. Numerous factors are contributing to this expected growth during the forecast period, including an upsurge in worldwide clinical trial activities, enhancements in healthcare infrastructure, increased awareness of uncommon diseases, an expanding gene therapy pipeline, and a rise in partnerships and collaborations. During the forecast period, several trends are projected to occur, such as the incorporation of technology into remote patient monitoring, innovating vector production platforms, the automation of biomanufacturing driven by technology, the development of gene therapies for extremely rare childhood Central Nervous System (CNS) diseases, and genomic screening integration in clinical environments._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp_x000D_
_x000D_
#What Market Forces Are Driving The Gene Therapy On Neurological Diseases Sector In 2025 And Beyond?#_x000D_
The escalating incidence of neurological conditions is poised to spur the expansion of the market for gene therapy on neurological diseases. Neurological disorders encompass medical conditions that impact the brain, spinal cord, and nerves, resulting in a myriad of symptoms such as cognitive, motor, and sensory impairments. The upward trend in neurological disorders is intertwined with the growing aged population, as age-related neuronal function deterioration, decreased brain plasticity, and enhanced oxidative stress promote the onset and progression of these conditions. Gene therapy for neurological diseases delivers assistance in managing these disorders by targeting the underlying genetic triggers, thus providing potential long-lasting, or even permanent, treatment alternatives. This offers improved patient results by rectifying or modifying gene functionality, alleviating symptoms, and reducing the necessity for recurrent interventions, thereby promoting an improved overall quality of life. For instance, as reported by the National Health Service, a UK-based government agency, by June 30, 2024, there were 487,432 patients diagnosed with dementia (a degenerative brain disorder affecting memory, cognition, and daily activities), marking an increase of 3,155 cases as compared with May 31, 2024. Consequently, the escalating incidence of neurological disorders is fueling the growth of the gene therapy on neurological diseases market._x000D_
_x000D_
#How Is The Global Gene Therapy On Neurological Diseases Market Categorized By Segments?#_x000D_
The gene therapy on neurological diseases market covered in this report is segmented_x000D_
_x000D_
1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy_x000D_
2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis_x000D_
3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes_x000D_
4) By Application: Hospital, Clinic, Other Applications_x000D_
_x000D_
Subsegments:_x000D_
1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus_x000D_
2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)_x000D_
_x000D_
#What Long-Term Trends Are Likely To Affect The Gene Therapy On Neurological Diseases Market?#_x000D_
Leading companies in the gene therapy on neurological diseases market are focusing their efforts on creating state-of-the-art viral delivery systems, like adeno-associated virus serotype 2 (AAV2) vector. This is to enhance the precision of gene delivery, increase effectiveness, lower the likelihood of immune responses, and facilitate long-term treatments. The adeno-associated virus serotype 2 (AAV2) vector is essentially a modified, non-pathogenic viral delivery system used in gene therapy for delivering remedial genes into specific cells, primarily neurons, for prolonged expression. For example, PTC Therapeutics Inc., a biopharmaceutical firm based in the United States, obtained approval from the U.S. Food and Drug Administration (FDA) in November 2024 for gene therapy to treat aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy employs an AAV2 vector to transport a functional version of the DDC gene into the putamen, which enhances dopamine production and thereby enhances motor functions. This one-time, intraputaminal infusion aims to maintain therapeutic benefits, substantially improving motor function and reducing crippling symptoms without the requirement for continued interventions._x000D_
_x000D_
#Which Firms Are Considered Leaders In The Gene Therapy On Neurological Diseases Market Space?#_x000D_
Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Neurocrine Biosciences Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Amicus Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG. _x000D_
_x000D_
#Get The Full Report Here:#_x000D_
_x000D_
#What Role Do Regional Policies And Investments Play In Gene Therapy On Neurological Diseases Market Expansion?#_x000D_
North America was the largest region in the gene therapy on neurological diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model